Ernexa Therapeutics Inc. 8-K

What Happened
Ernexa Therapeutics Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on July 1, 2026. As of the May 6, 2026 record date, 1,166,333 shares of common stock were outstanding; 619,741 shares (about 53.13%) were represented at the meeting, constituting a quorum. All five director nominees — James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner and William Wexler — were elected to serve until the 2027 Annual Meeting.

Key Details

• Shares outstanding (Record Date, May 6, 2026): 1,166,333; shares represented at meeting: 619,741 (≈53.13%).
• Director election votes (For / Withheld / Non-Votes):
  • James Bristol: 455,380 / 3,196 / 161,165
  • Peter Cicala: 455,121 / 3,455 / 161,165
  • Sanjeev Luther: 442,564 / 16,012 / 161,165
  • Elena Ratner: 455,633 / 2,943 / 161,165
  • William Wexler: 455,156 / 3,420 / 161,165
• Auditor ratification (Haskell & White LLP for FY2026): 590,236 for, 29,010 against, 495 abstentions.
• Adoption of the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan: 363,640 for, 94,840 against, 96 abstentions; 161,165 non-votes.

Why It Matters
The filing confirms board continuity with all nominees elected and retains Haskell & White LLP as the independent auditor, which maintains consistency in the company’s financial reporting oversight. Stockholder approval of the omnibus equity incentive plan authorizes the company to grant equity awards going forward — a tool commonly used for employee and executive compensation that may lead to future equity grants (and associated dilution as those awards are issued). These outcomes are governance items investors watch for signals about corporate oversight, compensation strategy, and potential effects on share count.